Zoran Bogdanovic Buys 178 Shares of Coca-Cola HBC AG (CCH.L) (LON:CCH) Stock

Zoran Bogdanovic Buys 178 Shares of Coca-Cola HBC AG (CCH.L) (LON:CCH) Stock


Coca-Cola HBC AG (CCH.L) (LON:CCH) insider Zoran Bogdanovic acquired 178 shares of the stock in a transaction that occurred on Tuesday, November 17th. The shares were bought at an average cost of GBX 2,280 ($29.79) per share, with a total value of £4,058.40 ($5,302.33).

Zoran Bogdanovic also recently made the following trade(s):

  • On Friday, October 16th, Zoran Bogdanovic purchased 215 shares of Coca-Cola HBC AG (CCH.L) stock. The shares were purchased at an average price of GBX 1,936 ($25.29) per share, for a total transaction of £4,162.40 ($5,438.20).
  • On Thursday, September 17th, Zoran Bogdanovic acquired 200 shares of Coca-Cola HBC AG (CCH.L) stock. The stock was purchased at an average cost of GBX 2,088 ($27.28) per share, with a total value of £4,176 ($5,455.97).

CCH stock traded down GBX 7 ($0.09) during midday trading on Wednesday, reaching GBX 2,268 ($29.63). 312,447 shares of the company were exchanged, compared to its average volume of 791,389. The stock’s 50-day simple moving average is GBX 1,947.56 and its 200 day simple moving average is GBX 2,006.62. Coca-Cola HBC AG has a 1-year low of GBX 1,393.10 ($18.20) and a 1-year high of GBX 2,933 ($38.32). The company has a debt-to-equity ratio of 121.81, a quick ratio of 0.85 and a current ratio of 1.08. The company has a market cap of $7.11 billion and a price-to-earnings ratio of 15.79.

Several research firms recently issued reports on CCH. Citigroup reissued a “buy” rating and set a GBX 2,500 ($32.66) target price on shares of Coca-Cola HBC AG (CCH.L) in a research note on Thursday, August 6th. Morgan Stanley restated an “overweight” rating on shares of Coca-Cola HBC AG (CCH.L) in a report on Tuesday, September 22nd. Credit Suisse Group reduced their target price on shares of Coca-Cola HBC AG (CCH.L) from GBX 2,550 ($33.32) to GBX 2,400 ($31.36) and set an “outperform” rating on the stock in a report on Thursday, August 6th. Deutsche Bank Aktiengesellschaft upped their price objective on Coca-Cola HBC AG (CCH.L) from GBX 2,400 ($31.36) to GBX 2,650 ($34.62) and gave the stock a “buy” rating in a research report on Thursday, November 12th. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Coca-Cola HBC AG (CCH.L) in a report on Wednesday, September 2nd. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of GBX 2,346.25 ($30.65).

(Ad)

The long-awaited Uranium Bull Market is here. Early indicators point to a surge toward all-time highs of $140. We’ve done the heavy lifting for you by identifying the top uranium stock – trading well below $1 – and sitting on a key asset in the safest high-grade uranium district on the planet.

Coca-Cola HBC AG (CCH.L) Company Profile

Coca-Cola HBC AG produces, distributes, and sells non-alcoholic ready-to-drink beverages. The company offers sparkling soft drinks; still drinks, including juices and fruit-based drinks, iced tea, and energy and sports drinks; and natural mineral, spring, and processed water. It markets and sells its products under the Coca-Cola, Fanta, Sprite, Amita, Avra, Deep RiverRock, Fruice, and Nestea brand names; and distributes third-party products, such as Monster energy drinks, and beer and premium spirits.

Read More: What causes a yield curve to invert?

Insider Buying and Selling by Quarter for Coca-Cola HBC AG (CCH.L) (LON:CCH)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

15 Healthcare Stocks that Analysts Love

There are more than 200 healthcare companies traded on public markets. Given the sheer number of pharmaceutical companies, medical research firms, hospital systems, and other healthcare stocks, it can be hard to identify which healthcare companies will outperform the market.

Fortunately, Wall Street’s brightest minds have already done this for us. Every year, analysts issue approximately 3,000 distinct recommendations for healthcare companies. Analysts don’t always get their “buy” ratings right, but it’s worth taking a hard look when several analysts from different brokerages and research firms are giving “strong-buy” and “buy” ratings to the same healthcare stock.

This slide show lists the 15 healthcare companies with the highest average analyst recommendations from Wall Street’s equities research analysts over the last 12 months.

View the “15 Healthcare Stocks that Analysts Love”.



Source link

2020-11-18 16:21:50

Leave a Reply

Your email address will not be published. Required fields are marked *